Skip to main content

Table 2 Basic characteristics of studies reporting on humanistic burden of LOPD

From: The humanistic burden of Pompe disease: are there still unmet needs? A systematic review

Publication

Quality rating

Study design

Geographic region

Population (sample size)

Disease severity

ERT status

Angelini 2009 [25]

5/9

Prospective cohort

Italy

Symptomatic LOPD patients recruited from three collaborating University Centers (n = 11)

Symptomatic (≥2 on the Gardner-Medwin and Walton functional scale)

ERT

Aslan 2016 [26]

6/9

Prospective cohort

Turkey

Subjects with a genetically confirmed diagnosis of LOPD (n = 8)

Not stated

ERT

Boentert 2015 [34]

7/9

Cross-sectional

Germany

LOPD patients recruited from specialized outpatient clinics at three neuromuscular centers (n = 65)

Not stated (outpatients)

ERT

Freedman 2013 [35]

3/9

Cross-sectional

Australia

LSD patients selected through purposive criterion sampling representing patients receiving ERT to treat a LSD, siblings and parents (9 parents, 4 patients, 3 siblings)

Not stated

ERT

Furusawa 2012 [40]

NA

Case series

Japan

Patients with LOPD who had undergone ERT at the National Center Hospital (n = 5)

Wheelchair bound (n = 4) or able to stand for a few minutes (n = 1)

ERT

Güngör 2013 [36]

8/9

Cross-sectional

Germany, Netherlands

LOPD patients recruited through the German patient organization or through Erasmus MC in The Netherlands (n = 124)

Full range of severities (mild to fully wheelchair/ventilator dependent)

ERT

Güngör 2016 [29]

3/9

Prospective cohort

Australia, Canada, France, Germany, Netherlands, US, UK, others

Child and adult Pompe disease patients included through national support groups (n = 174)

Full range of severities (mild to fully wheelchair/ventilator dependent)

ERT-transition (minimum 6 months follow-up before and after ERT)

Hagemans 2007 [33]

5/9

Cross-sectional

Multiple countries

LOPD patients recruited through patient organizations affiliated with the IPA (n = 257)

Full range of severities (mild to fully wheelchair/ventilator dependent)

No ERT

Hagemans 2004 [32]

5/9

Cross-sectional

Australia, Germany, the Netherlands, the UK, the US

LOPD (n = 210)

Full range of severities (mild to fully wheelchair/ventilator dependent)

No ERT

Kanters 2013 [37]

5/9

Cross-sectional

Netherlands

All patients at the Center for Lysosomal and Metabolic diseases in Rotterdam receiving informal care plus one caregiver per patient (67 patients; 67 informal caregivers)

Range

ERT

Karabul 2014a [38]

3/9

Cross-sectional

UK

Adult LOPD patients (n = 25)

Not stated

ERT

Karabul 2014b [39]

6/9

Cross-sectional

Germany

Adult LOPD patients (n = 73)

Not stated

ERT

Regnery 2012 [27]

5/9

Prospective cohort

Germany

Adult LOPD patients from university-based centers (n = 38)

Various

ERT

Strothotte 2010 [28]

6/9

Prospective cohort

Germany

LOPD patients treated in participating German university-based centers (n = 44)

Various

ERT

Van Capelle 2008 [41]

5/9

Case series

Netherlands

Two severely affected LOPD patients and one moderately affected LOPD patient (n = 3)

Moderate (n = 1) to severe (n = 2)

ERT

van der Meijden 2015 [30]

7/9

Prospective cohort

Australia, Canada, France, Germany, Netherlands, US, UK, others

Child and adult Pompe disease patients included through national support groups (n = 408)

Full range of severities (mild to fully wheelchair/ventilator dependent)

ERT-transition

van der Ploeg 2010 [31]

7/9

RCT

US and Europe (eight centers)

LOPD patients, 8 years of age or older, ambulatory, and free of invasive ventilation (n = 90)

Range (excluded if invasive ventilation or if required noninvasive ventilation while awake and upright)

ERT

  1. ‘ERT-transition’ studies refer to those initiated before the approval of ERT but continuing into the post-ERT era
  2. Quality rating refers to a quality score assigned to each publication considering characteristics that could introduce bias, using the following tools: 1) Newcastle-Ottawa Scale for cohort studies and case-control studies [22]; 2) Adapted Newcastle-Ottawa Scale for cross-sectional studies [22]; 3) AMSTAR measurement tool for reviews [23]; 4) Cochrane risk of bias assessment tool for randomized controlled trials [24]. The maximum score for the Newcastle-Ottawa Scale is 9
  3. IPA: International Pompe Association; LOPD: Late-onset Pompe disease; LSD: Lysosomal storage disorders; MC: Medical center; RCT: Randomized controlled trial